Drug developer Merck & Co. said Friday a European advisory committee recommended approval for the company's fertility drug Elonva.
The Committee for Medicinal Products for Human Use of The European Medicines Agency made the recommendation. The European Commission will consider it when determining whether to approve the treatment. If approved, the injectable treatment could be sold in all European Union member states.
Shares of Merck rose 65 cents to $35.98 in morning trading.